Fludarabin Teva
Fludarabine phosphate – Purine analogue for chronic lymphocytic leukemia
Fludarabin Teva contains fludarabine phosphate, a purine analogue antineoplastic agent used to treat B-cell chronic lymphocytic leukemia (B-CLL). It works by interfering with DNA synthesis in cancer cells, inhibiting their growth and division. This medication is administered intravenously in hospital settings under the supervision of a specialist physician experienced in cancer treatment. Understanding its therapeutic uses, potential risks, required monitoring, and important safety precautions is essential for patients and caregivers involved in CLL treatment.
Quick Facts
Key Takeaways
- Fludarabin Teva is a purine analogue antineoplastic used primarily for treating B-cell chronic lymphocytic leukemia (B-CLL) in patients with adequate bone marrow function.
- It causes significant immunosuppression and myelosuppression; regular blood monitoring is mandatory throughout treatment and afterward.
- Life-threatening autoimmune hemolytic anemia can occur during or after treatment, requiring immediate medical intervention.
- Blood transfusions must use irradiated blood products only, as non-irradiated blood can cause fatal transfusion-associated graft-versus-host disease.
- Women must use effective contraception for 6 months after treatment, and men for at least 3 months; the drug must not be used during pregnancy or breastfeeding.
What Is Fludarabin Teva and What Is It Used For?
Fludarabin Teva belongs to a class of anticancer medications known as purine analogues or antimetabolites. The active substance, fludarabine phosphate, is a synthetic nucleoside analogue that interferes with the fundamental processes of DNA synthesis within cancer cells. After entering the body, fludarabine phosphate is rapidly converted to its active form, which is then taken up by cells where it disrupts the normal cell division machinery, ultimately preventing cancer cells from reproducing and leading to their death.
In chronic lymphocytic leukemia (CLL), the body produces an excessive number of abnormal white blood cells called lymphocytes. These dysfunctional lymphocytes accumulate in the blood, bone marrow, and lymph nodes throughout the body. As the disease progresses, lymph nodes in various regions begin to enlarge, and the abnormal lymphocytes crowd out healthy blood cells. This disruption of normal blood cell production can lead to increased susceptibility to infections (due to reduced functional white blood cells), anemia (due to decreased red blood cells), and abnormal bleeding or bruising (due to low platelet counts).
Fludarabine is particularly effective against B-lymphocytes, which are the cell type predominantly affected in B-CLL. The drug achieves high intracellular concentrations in lymphoid cells, making it especially potent against the malignant B-cell population. Clinical trials have demonstrated that fludarabine-based regimens achieve higher overall response rates and longer progression-free survival compared to many traditional alkylating agent-based chemotherapy protocols for CLL.
First-line treatment with Fludarabin Teva should only be initiated in patients with advanced-stage CLL who are experiencing disease-related symptoms or showing clear evidence of disease progression. This approach aligns with international treatment guidelines from organizations such as the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) and the National Comprehensive Cancer Network (NCCN), which recommend a watch-and-wait strategy for early-stage, asymptomatic CLL. Fludarabine may also be used in combination with other agents, most notably cyclophosphamide and rituximab in the well-established FCR (fludarabine, cyclophosphamide, rituximab) regimen, which has been a standard of care for fit patients with CLL.
What Should You Know Before Taking Fludarabin Teva?
Before starting treatment with Fludarabin Teva, your healthcare team will perform comprehensive evaluations to ensure that this medication is appropriate for your specific medical situation. These assessments typically include complete blood counts, kidney function tests, liver function tests, and a review of your complete medical history. It is crucial that you provide your doctor with a full picture of your health, including all medications you are taking, any previous treatments for cancer, and any existing medical conditions.
Contraindications
Fludarabin Teva must not be used in the following situations:
- Allergy to fludarabine phosphate or any of the other ingredients in the medication (mannitol, sodium hydroxide, water for injections).
- Breastfeeding – fludarabine must not be used during breastfeeding as the drug may pass into breast milk and harm the nursing infant.
- Severely impaired kidney function – because fludarabine is primarily eliminated through the kidneys, severe renal impairment (creatinine clearance below 30 ml/min) significantly increases the risk of toxicity.
- Decompensated hemolytic anemia – a type of anemia caused by the immune system destroying red blood cells. Your doctor will determine whether you have this condition through specific blood tests.
Warnings and Precautions
Several important warnings apply to treatment with Fludarabin Teva. Discuss the following with your doctor before treatment begins:
Autoimmune complications: During treatment with fludarabine, the immune system may begin to attack the body's own healthy cells. This can manifest as autoimmune hemolytic anemia (destruction of red blood cells), autoimmune thrombocytopenia (destruction of platelets), or other autoimmune disorders. These conditions can be life-threatening. If they develop, your doctor will discontinue fludarabine treatment and initiate appropriate therapy, which may include corticosteroids and transfusions with irradiated blood products.
Tumor lysis syndrome: In patients with a high tumor burden, fludarabine can rapidly destroy large numbers of cancer cells, releasing their cellular contents into the bloodstream. This phenomenon, known as tumor lysis syndrome (TLS), can overwhelm the kidneys and lead to acute kidney failure, dangerous electrolyte imbalances, and cardiac complications. TLS is most likely to occur during the first week of treatment. Your doctor may prescribe preventive measures including adequate hydration and medications such as allopurinol to reduce the risk.
Neurological toxicity: At the recommended dose, long-term effects on the central nervous system have not been fully characterized. Patients treated with doses up to 26 cycles at the standard dose have generally tolerated the medication. However, when fludarabine has been administered at doses approximately four times the recommended level, severe and irreversible neurological effects have occurred, including delayed-onset blindness, coma, and death. Some of these symptoms appeared 60 days or more after treatment cessation. Neurological symptoms at any dose should be reported to your healthcare provider immediately.
Leukoencephalopathy: Cases of leukoencephalopathy, acute toxic leukoencephalopathy, and posterior reversible encephalopathy syndrome (PRES) have been reported both at higher-than-recommended doses and at recommended doses, particularly when fludarabine is combined with other chemotherapy agents. Symptoms may include headache, nausea, vomiting, seizures, visual disturbances including vision loss, altered mental state, and neuromuscular symptoms such as weakness in the arms and legs. These conditions can be permanent, life-threatening, or fatal. If suspected, treatment will be permanently discontinued.
Skin cancer risk: If you have a history of skin cancer, the condition may worsen or recur during or after treatment with fludarabine. Additionally, new skin cancers may develop during or after therapy. Your doctor will monitor you for any skin changes throughout your treatment course.
Pregnancy and Breastfeeding
Fludarabine phosphate poses significant risks to reproductive health and fetal development. Based on animal studies and limited human data, fludarabine can cause harm to an unborn baby, including birth defects, early miscarriage, and premature birth. The following precautions are essential:
- Women of childbearing potential must use reliable contraception during treatment and for at least 6 months after the last dose. If pregnancy occurs during treatment, the treating physician must be informed immediately.
- Men must use reliable contraception during treatment and for at least 3 months after the last dose. Men should also seek counseling regarding sperm preservation (cryopreservation) before treatment begins, as fludarabine may impair male fertility.
- Breastfeeding is contraindicated during fludarabine treatment. Women must not breastfeed while receiving this medication.
Special Populations
Kidney impairment: If you have moderate kidney problems or are over 65 years old, kidney function will be monitored regularly with blood tests throughout treatment. Dose reductions may be necessary based on creatinine clearance measurements. Patients with severe renal impairment (creatinine clearance below 30 ml/min) must not receive fludarabine.
Liver impairment: Patients with liver disease will receive fludarabine with additional caution and closer monitoring. Your doctor will assess liver function before and during treatment.
Elderly patients: Patients over 75 years of age will be monitored with particular attention, as they may be more susceptible to the drug's effects and side effects, particularly myelosuppression and infections.
Children and adolescents: The safety and efficacy of fludarabine in patients under 18 years of age have not been established. This medication is not recommended for use in pediatric patients.
Driving and Operating Machinery
Fludarabine may cause fatigue, visual disturbances, confusion, agitation, or seizures. Patients should not drive or operate machinery until they are certain that they are not adversely affected. You are personally responsible for assessing your fitness to drive or perform tasks requiring alertness while on this medication.
How Does Fludarabin Teva Interact with Other Drugs?
Drug interactions can significantly alter the effectiveness or safety of fludarabine treatment. It is essential to inform your doctor and pharmacist about every medication you are currently taking, have recently taken, or may plan to take, including prescription medicines, over-the-counter drugs, herbal supplements, and vitamins. Some interactions are potentially life-threatening and represent absolute contraindications to concurrent use.
Major Interactions
| Interacting Drug | Severity | Effect | Recommendation |
|---|---|---|---|
| Pentostatin (deoxycoformycin) | Contraindicated | Severe, potentially fatal pulmonary toxicity | Must not be used together |
| Dipyridamole | Major | Reduces cellular uptake of fludarabine, decreasing efficacy | Avoid concurrent use; discuss alternatives |
| Cytarabine (Ara-C) | Moderate | Increased active metabolite of cytarabine in leukemia cells; overall plasma levels unchanged | Monitor closely if combination is used |
| Live vaccines | Major | Risk of vaccine-strain infection due to immunosuppression | Avoid live vaccines during and after treatment |
| Other immunosuppressants | Moderate | Additive immunosuppression; increased infection risk | Close monitoring for infections |
Minor Interactions
Beyond the major interactions listed above, fludarabine may interact with various other medications through shared metabolic pathways or additive effects on the bone marrow. Other antineoplastic agents used in combination regimens (such as cyclophosphamide in the FC or FCR protocol) may increase the risk and severity of myelosuppression. While these combinations are used intentionally in clinical practice, they require careful dose adjustments and intensified monitoring by the treating oncologist or hematologist.
Vaccination with inactivated (non-live) vaccines may be less effective during fludarabine treatment due to the immunosuppressive state. Your healthcare team will advise you on the appropriate timing for any vaccinations in relation to your treatment schedule. In general, live vaccines should be completely avoided during and for a period after fludarabine treatment, as the severely immunocompromised state could allow the weakened vaccine organisms to cause actual infection.
What Is the Correct Dosage of Fludarabin Teva?
Fludarabin Teva is always administered under the direct supervision of a physician who specializes in cancer treatment. The dose is individualized based on your body surface area, which is calculated from your height and weight. Your doctor will determine the exact dose and monitor your response throughout the treatment course.
Adults
Standard Adult Dosage
Dose: 25 mg fludarabine phosphate per m² body surface area
Route: Intravenous injection or infusion (approximately 30 minutes)
Schedule: Once daily for 5 consecutive days
Cycle: Repeated every 28 days
Duration: Usually 6 cycles (approximately 6 months), until optimal response is achieved
The infusion involves delivering the medication directly into the bloodstream through a vein, typically over a period of approximately 30 minutes. Your healthcare team will ensure that the infusion line is properly positioned within the vein, as inadvertent extravasation (leakage outside the vein) should be avoided, although no serious local reactions have been reported in such cases.
The treatment duration depends on how well the medication works and how well you tolerate it. Your doctor may reduce the dose or delay treatment cycles if you experience significant side effects, particularly bone marrow suppression. Regular blood tests will be performed to monitor your blood cell counts and guide dosing decisions.
Renal Impairment Dose Adjustments
| Creatinine Clearance | Kidney Function | Dose Recommendation |
|---|---|---|
| > 70 ml/min | Normal | Full dose (25 mg/m²) |
| 30–70 ml/min | Moderate impairment | Reduced dose; close monitoring of kidney function |
| < 30 ml/min | Severe impairment | Contraindicated – do not use |
Children
The safety and efficacy of Fludarabin Teva in children and adolescents under 18 years of age have not been established. This medication is not recommended for use in the pediatric population.
Elderly Patients
There is no specific dose adjustment based solely on age. However, because kidney function naturally declines with age, elderly patients (particularly those over 65) will have their renal function monitored regularly. Patients over 75 years of age require particularly careful monitoring. Dose adjustments will be made as necessary based on creatinine clearance values and tolerance to treatment.
Missed Dose
Since Fludarabin Teva is administered in a clinical setting by healthcare professionals, missed doses are uncommon. If you believe you may have missed a scheduled dose, contact your treatment team as soon as possible. Your doctor will determine the appropriate time for your next dose. Do not attempt to make up for a missed dose on your own.
Overdose
In the event of a suspected overdose, treatment will be discontinued immediately and supportive care will be provided. This may include blood transfusions (with irradiated products), antimicrobial therapy for infections, and intensive monitoring of organ function. The onset of some overdose-related symptoms, particularly neurological effects, may be significantly delayed.
What Are the Side Effects of Fludarabin Teva?
Like all chemotherapy medications, Fludarabin Teva can cause side effects, although not everyone experiences them. Some side effects are common and manageable, while others are rare but potentially life-threatening. Your healthcare team will monitor you closely for adverse effects throughout your treatment course and for a period afterward. It is important to report any new or worsening symptoms to your doctor promptly.
Very Common
- Infections (including serious infections and opportunistic infections)
- Pneumonia and other respiratory infections
- Neutropenia (low white blood cell count)
- Thrombocytopenia (low platelet count, causing bruising and bleeding)
- Anemia (low red blood cell count)
- Cough
- Nausea, vomiting, and diarrhea
- Fever (pyrexia)
- Fatigue
- Weakness (asthenia)
Common
- Secondary blood cancers (myelodysplastic syndrome, acute myeloid leukemia)
- Bone marrow suppression (myelosuppression)
- Severe appetite loss leading to weight loss (anorexia)
- Peripheral neuropathy (numbness or weakness in arms and legs)
- Visual disturbances
- Mouth sores (stomatitis)
- Skin rash
- Swelling due to fluid retention (edema)
- Mucositis (inflammation of mucous membranes in the digestive tract)
- Chills
- General malaise (feeling of being unwell)
Uncommon
- Autoimmune disorders (including autoimmune hemolytic anemia and autoimmune thrombocytopenia)
- Tumor lysis syndrome
- Confusion
- Pulmonary toxicity, lung fibrosis, or pneumonitis
- Shortness of breath (dyspnea)
- Gastrointestinal bleeding (stomach or intestinal)
- Abnormal liver or pancreatic enzyme levels
Rare
- EBV-associated lymphoproliferative disease
- Coma
- Seizures
- Agitation
- Blindness
- Optic neuritis or optic neuropathy
- Heart failure
- Cardiac arrhythmia (irregular heartbeat)
- Skin cancer
- Stevens-Johnson syndrome or toxic epidermal necrolysis (Lyell syndrome)
Frequency Not Known
- Cerebral hemorrhage (brain bleeding)
- Leukoencephalopathy, acute toxic leukoencephalopathy, or PRES
- Hemorrhagic cystitis (bladder inflammation causing painful urination and blood in urine)
- Pulmonary hemorrhage (bleeding into the lungs)
It is important to understand that the risk of developing secondary malignancies (such as myelodysplastic syndrome or acute myeloid leukemia) exists with fludarabine treatment. Most patients who developed these conditions had previously been treated with other anticancer agents (particularly alkylating agents or topoisomerase inhibitors) or had received radiation therapy. The contribution of fludarabine alone versus prior therapies is difficult to determine in individual cases.
The immune system may remain suppressed for a prolonged period after fludarabine treatment – potentially up to a year or more. During this time, patients remain at increased risk for infections, including opportunistic infections caused by organisms that would not normally cause disease in individuals with a healthy immune system. Late reactivation of viruses, such as herpes zoster (shingles), can also occur. Discuss preventive measures with your healthcare team.
How Should You Store Fludarabin Teva?
Proper storage of Fludarabin Teva is essential to maintain the medication's effectiveness and safety. As this medication is administered in a clinical setting, storage is primarily the responsibility of healthcare facilities. However, it is important for patients to understand the storage requirements.
- Temperature: Store the unopened vials in a refrigerator at 2–8°C (36–46°F).
- Freezing: The medication must not be frozen.
- Shelf life: Do not use after the expiration date printed on the carton and vial (marked as EXP). The expiration date refers to the last day of that month.
- After dilution: Chemical and physical stability after dilution has been demonstrated for up to 5 days when stored in a refrigerator (2–8°C) or at room temperature, when diluted in sodium chloride 0.9% or glucose 5% solutions.
- Microbiological considerations: From a microbiological standpoint, the diluted solution should be used immediately. If not used immediately, storage should not normally exceed 24 hours at 2–8°C unless dilution was performed under controlled and validated aseptic conditions.
- Keep out of reach: Keep the medication out of the sight and reach of children.
- Disposal: Do not dispose of the medication through wastewater or household waste. It must be disposed of in accordance with local guidelines for cytotoxic materials.
What Does Fludarabin Teva Contain?
Understanding the complete composition of your medication helps identify potential allergens and ensures safe administration. Fludarabin Teva is formulated as a concentrate for solution for injection or infusion.
Active Substance
Each milliliter of concentrate contains 25 mg of fludarabine phosphate. Each 2 ml vial therefore contains a total of 50 mg of fludarabine phosphate.
Inactive Ingredients (Excipients)
- Mannitol (E421) – a sugar alcohol used as a stabilizer and tonicity agent.
- Sodium hydroxide (E524) – used to adjust the pH of the solution.
- Water for injections – the vehicle for the solution.
Physical Appearance
Fludarabin Teva is a clear, colorless to slightly brownish-yellow solution, essentially free from visible particles. It is supplied in a colorless glass vial sealed with a rubber stopper, aluminum seal, and a plastic snap-off cap. Each package contains one vial. Only clear solutions free from particles should be used; do not use the product if the container is damaged.
Preparation for Administration
Fludarabin Teva must be prepared for administration by trained healthcare professionals following strict cytotoxic handling protocols. The required dose is drawn into a syringe and then diluted:
- For IV bolus injection: Dilute in 10 ml of sodium chloride 0.9%.
- For IV infusion: Dilute in 100 ml of sodium chloride 0.9% and infuse over approximately 30 minutes.
The medication may also be diluted in glucose 5% (50 mg/ml) solution. Pregnant healthcare personnel must not handle this medication. Protective gloves and safety goggles must be worn during preparation to prevent accidental exposure.
Frequently Asked Questions About Fludarabin Teva
Fludarabin Teva is used for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), a type of blood cancer affecting white blood cells. It is prescribed for patients who have sufficient healthy blood cell production in their bone marrow. First-line treatment is typically initiated only when the disease has progressed to an advanced stage with symptoms or clear signs of worsening. It may be used alone or in combination with other medications such as cyclophosphamide and rituximab.
The most serious side effects include severe myelosuppression (bone marrow suppression) leading to life-threatening infections and bleeding, autoimmune hemolytic anemia where the immune system attacks red blood cells, tumor lysis syndrome affecting kidney function, and neurotoxicity. At very high doses, irreversible central nervous system damage including blindness, coma, and death have occurred. All patients require regular blood monitoring throughout treatment.
Fludarabine causes profound and prolonged immunosuppression. Non-irradiated blood contains viable donor lymphocytes that, in a severely immunocompromised patient, can cause transfusion-associated graft-versus-host disease (TA-GvHD). This condition occurs when donor white blood cells attack the recipient's tissues and is almost always fatal. Irradiation of blood products inactivates these donor lymphocytes, preventing this complication. This requirement applies both during and after fludarabine treatment.
Live vaccines must be avoided during and for a significant period after fludarabine treatment due to the risk of developing the actual disease from the weakened vaccine organism. Inactivated vaccines may be administered but are likely to produce a reduced immune response, making them less effective. Your hematologist or oncologist will advise you on the appropriate timing for any vaccinations based on your individual immune recovery.
A typical treatment course consists of 5 days of intravenous infusions repeated every 28 days for approximately 6 cycles, lasting about 6 months in total. However, the actual duration depends on how well you respond to the treatment and how well you tolerate the side effects. Your doctor may extend or shorten the treatment course, adjust the dose, or delay cycles based on your individual response and blood test results.
Tumor lysis syndrome (TLS) occurs when chemotherapy rapidly destroys a large number of cancer cells, releasing their contents into the bloodstream. This can overwhelm the kidneys and cause dangerous electrolyte imbalances, potentially leading to kidney failure and cardiac complications. Patients with a high tumor burden (large number of cancer cells or significantly enlarged lymph nodes) are at greatest risk, particularly during the first week of treatment. Preventive measures include adequate hydration and sometimes medications like allopurinol.
Unopened vials of Fludarabin Teva should be stored in a refrigerator at 2–8°C and must not be frozen. After dilution, the solution is chemically stable for up to 5 days in a refrigerator or at room temperature. However, from a microbiological safety perspective, it should ideally be used immediately. Any unused solution must be disposed of according to local guidelines for handling cytotoxic waste – it should never be discarded in regular household waste or wastewater.
References
- European Medicines Agency (EMA). Fludarabine phosphate – Summary of Product Characteristics. EMA/CHMP. Available at: www.ema.europa.eu.
- Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760. doi:10.1182/blood-2017-09-806398.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 1.2026.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List (2023). Geneva: World Health Organization.
- Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23-33. doi:10.1016/j.annonc.2020.09.019.
- Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343(24):1750-1757. doi:10.1056/NEJM200012143432402.
- Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208-215. doi:10.1182/blood-2015-06-651125.
- British National Formulary (BNF). Fludarabine phosphate. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk.
- Johnson S, Smith AG, Löffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet. 1996;347(9013):1432-1438.
- Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-4088. doi:10.1200/JCO.2005.12.051.
Editorial Team
This article was prepared by the iMedic Medical Editorial Team, comprising board-certified specialists in hematology, oncology, and clinical pharmacology. All content undergoes rigorous peer review for medical accuracy and is updated regularly to reflect the latest evidence-based guidelines.
Reviewed by specialist physicians in hematology-oncology with expertise in chronic lymphocytic leukemia treatment and clinical pharmacology of antineoplastic agents.
Content follows WHO, EMA, NCCN, and ESMO guidelines. Evidence graded using the GRADE framework. No pharmaceutical industry funding or sponsorship.
Last medical review: | Next scheduled review: